First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Filip Jankú et al.|Cancer Discovery|2017Cited by 418
Canstatin Inhibits Akt Activation and Induces Fas-dependent Apoptosis in Endothelial CellsDavid J. Panka, James W. Mier|Journal of Biological Chemistry|2003Cited by 125